Analysis in conditional cannabinoid 1 receptor-knockout mice reveals neuronal subpopulation-specific effects on epileptogenesis in the kindling paradigm

Neurobiology of Disease

Volumn 73, Issue , 2015, Pages 334-347

  von Ruden E L ^a   Jafari, M ^a   Bogdanovic, R M ^a   Wotjak, C T ^b   Potschka, H ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Amygdala; CB1; Endovanilloid; GABA; Glutamate; Hyperexcitable network; Ictogenesis; Neurogenesis; Seizure; TRPV1

Indexed keywords

4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; RIMONABANT; VANILLOID RECEPTOR 1; 4 AMINOBUTYRIC ACID; ANILIDE; BROXURIDINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE I; CAMK1 PROTEIN, MOUSE; CANNABINOID RECEPTOR ANTAGONIST; CINNAMIC ACID DERIVATIVE; CNR1 PROTEIN, RAT; N-(3-METHOXYPHENYL)-4-CHLOROCINNAMANILIDE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; TRPV1 PROTEIN, MOUSE; VANILLOID RECEPTOR;

AFTERDISCHARGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CB1R GENE; CELL SUBPOPULATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; EPILEPTOGENESIS; FOREBRAIN; GABAERGIC SYSTEM; GENE; GENE DELETION; GENOTYPE; HIPPOCAMPUS; ICTOGENESIS; IMMUNOREACTIVITY; KINDLING; KNOCKOUT MOUSE; MALE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROMODULATION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN TARGETING; SEIZURE; TEMPORAL LOBE EPILEPSY; TONIC CLONIC SEIZURE; TRPV1 GENE; ANIMAL; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; EPILEPSY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY;

ANILIDES; ANIMALS; BROMODEOXYURIDINE; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 1; CANNABINOID RECEPTOR ANTAGONISTS; CINNAMATES; DISEASE MODELS, ANIMAL; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; GENE EXPRESSION REGULATION; KINDLING, NEUROLOGIC; MALE; MICE; MICE, KNOCKOUT; NEUROGENESIS; NEURONS; PIPERIDINES; PROSENCEPHALON; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; TRPV CATION CHANNELS;

EID: 84909983207     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.08.001     Document Type: Article

References (70)

1. Aguado T., Monory K., Palazuelos J., Stella N., Cravatt B., Lutz B., Marsicano G., Kokaia Z., Guzman M., Galve-Roperh I. The endocannabinoid system drives neural progenitor proliferation. FASEB J. 2005, 19(12):1704-1706.
2. Bhaskaran M.D., Smith B.N. Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy. Exp. Neurol. 2010, 223(2):529-536.
3. Blumcke I., Becker A.J., Klein C., Scheiwe C., Lie A.A., Beck H., Waha A., Friedl M.G., Kuhn R., Emson P., Elger C., Wiestler O.D. Temporal lobe epilepsy associated up-regulation of metabotropic glutamate receptors: correlated changes in mGluR1 mRNA and protein expression in experimental animals and human patients. J. Neuropathol. Exp. Neurol. 2000, 59(1):1-10.
4. Bojnik E., Turunc E., Armagan G., Kanit L., Benyhe S., Yalcin A., Borsodi A. Changes in the cannabinoid (CB1) receptor expression level and G-protein activation in kainic acid induced seizures. Epilepsy Res. 2012, 99(1-2):64-68.
5. Casanova E., Fehsenfeld S., Mantamadiotis T., Lemberger T., Greiner E., Stewart A.F., Schutz G. A CamKIIalpha iCre BAC allows brain-specific gene inactivation. Genesis 2001, 31(1):37-42.
6. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389(6653):816-824.
7. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., Koltzenburg M., Basbaum A.I., Julius D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000, 288(5464):306-313.
8. Cavanaugh D.J., Chesler A.T., Jackson A.C., Sigal Y.M., Yamanaka H., Grant R., O'Donnell D., Nicoll R.A., Shah N.M., Julius D., Basbaum A.I. Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells. J. Neurosci. 2011, 31(13):5067-5077.
9. Conklin B.R., Hsiao E.C., Claeysen S., Dumuis A., Srinivasan S., Forsayeth J.R., Guettier J.M., Chang W.C., Pei Y., McCarthy K.D., Nissenson R.A. Engineering GPCR signaling pathways with RASSLs. Nat. Methods 2008, 5(8):673-678.
10. Deisseroth K. Optogenetics. Nat. Methods 2011, 8(1):26-29.
11. Deshpande L.S., Blair R.E., Ziobro J.M., Sombati S., Martin B.R., DeLorenzo R.J. Endocannabinoids block status epilepticus in cultured hippocampal neurons. Eur. J. Pharmacol. 2007, 558(1-3):52-59.
12. Docherty R.J., Yeats J.C., Piper A.S. Capsazepine block of voltage-activated calcium channels in adult rat dorsal root ganglion neurones in culture. Br. J. Pharmacol. 1997, 121(7):1461-1467.
13. Dudek F.E., Pouliot W.A., Rossi C.A., Staley K.J. The effect of the cannabinoid-receptor antagonist, SR141716, on the early stage of kainate-induced epileptogenesis in the adult rat. Epilepsia 2010, 51(Suppl. 3):126-130.
14. Echegoyen J., Armstrong C., Morgan R.J., Soltesz I. Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model. Epilepsy Res. 2009, 85(1):123-127.
15. Egertová M., Elphick M.R. Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB1. J. Comp. Neurol. 2000, 422(2):159-171.
16. Falenski K.W., Carter D.S., Harrison A.J., Martin B.R., Blair R.E. DeLorenzoTemporal characterization of changes in hippocampal cannabinoid CB(1) receptor expression following pilocarpine-induced status epilepticus. Brain Res. 2009, 1262:64-72.
17. Farrell M.S., Roth B.L. Pharmacosynthetics: Reimagining the pharmacogenetic approach. Brain Res. 2013, 1511:6-20.
18. Fogaca M.V., Galve-Roperh I., Guimaraes F.S., Campos A.C. Cannabinoids, neurogenesis and antidepressant drugs: is there a link?. Curr. Neuropharmacol. 2013, 11(3):263-275.
19. Gill C.H., Randall A., Bates S.A., Hill K., Owen D., Larkman P.M., Cairns W., Yusaf S.P., Murdock P.R., Strijbos P.J., Powell A.J., Benham C.D., Davies C.H. Characterization of the human HCN1 channel and its inhibition by capsazepine. Br. J. Pharmacol. 2004, 143(3):411-421.
20. Goddard G.V., McIntyre D.C., Leech C.K. A permanent change in brain function resulting from daily electrical stimulation. Exp. Neurol. 1969, 25(3):295-330.
21. Goncalves M.B., Suetterlin P., Yip P., Molina-Holgado F., Walker D.J., Oudin M.J., Zentar M.P., Pollard S., Yáñez-Muñoz R.J., Williams G., Walsh F.S., Pangalos M.N., Doherty P. A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner. Mol. Cell. Neurosci. 2008, 38(4):526-536.
22. Gonzalez-Reyes L.E., Ladas T.P., Chiang C.C., Durand D.M. TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo. Exp. Neurol. 2013, 250C:321-332.
23. Guggenhuber S., Monory K., Lutz B., Klugmann M. AAV vector-mediated overexpression of CB1 cannabinoid receptor in pyramidal neurons of the hippocampus protects against seizure-induced excitoxicity. PLoS One 2010, 5(12):e15707.
24. Gunthorpe M.J., Rami H.K., Jerman J.C., Smart D., Gill C.H., Soffin E.M., Luis Hannan S., Lappin S.C., Egerton J., Smith G.D., Worby A., Howett L., Owen D., Nasir S., Davies C.H., Thompson M., Wyman P.A., Randall A.D., Davis J.B. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 2004, 46(1):133-149.
25. Han P., Korepanova A., Vos M., Moreland R., Chiu M., Faltynek C. Quantification of TRPV1 protein levels in rat tissues to understand its physiological roles. J. Mol. Neurosci. 2013, 50(1):23-32.
26. Hunt R.F., Hortopan G.A., Gillespie A., Baraban S.C. A novel zebrafish model of hyperthermia-induced seizures reveals a role for TRPV4 channels and NMDA-type glutamate receptors. Exp. Neurol. 2012, 237(1):199-206.
27. Jafari M., Haist V., Baumgärtner W., Wagner S., Stein V.M., Tipold A., Wendt H., Potschka H. Impact of Theiler's virus infection on hippocampal neuronal progenitor cells: differential effects in two mouse strains. Neuropathol. Appl. Neurobiol. 2012, 38(7):647-664.
28. Jafari M., Soerensen J., Bogdanović R.M., Dimou L., Götz M., Potschka H. Long-term genetic fate mapping of adult generated neurons in a mouse temporal lobe epilepsy model. Neurobiol. Dis. 2012, 48(3):454-463.
29. Kandratavicius L., Rosa-Neto P., Monteiro M.R., Guiot M.C., Assirati J.A., Carlotti C.G., Kobayashi E., Leite J.P. Distinct increased metabotropic glutamate receptor type 5 (mGluR5) in temporal lobe epilepsy with and without hippocampal sclerosis. Hippocampus 2013, 23(12):1212-1230.
30. Karlocai M.R., Toth K., Watanabe M., Ledent C., Juhasz G., Freund T.F., Magloczky Z. Redistribution of CB1 cannabinoid receptors in the acute and chronic phases of pilocarpine-induced epilepsy. PLoS One 2011, 6(11):e27196.
31. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med. 2008, 14(9):923-930.
32. Kong W.L., Min J.W., Liu Y.L., Li J.X., He X.H., Peng B.W. Role of TRPV1 in susceptibility to PTZ-induced seizure following repeated hyperthermia challenges in neonatal mice. Epilepsy Behav. 2014, 31:276-280.
33. Kow R.L., Jiang K., Naydenov A.V., Le J.H., Stella N., Nathanson N.M. Modulation of pilocarpine-induced seizures by cannabinoid receptor 1. PLoS One 2014, 9(4):e95922.
34. Liu L., Simon S.A. Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia. Neurosci. Lett. 1997, 228(1):29-32.
35. Loscher W., Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol. Rev. 2010, 62(4):668-700.
36. Lutz B. On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. Biochem. Pharmacol. 2004, 68(9):1691-1698.
37. Magloczky Z., Toth K., Karlocai R., Nagy S., Eross L., Czirjak S., Vajda J., Rasonyi G., Kelemen A., Juhos V., Halasz P., Mackie K., Freund T.F. Dynamic changes of CB1-receptor expression in hippocampi of epileptic mice and humans. Epilepsia 2010, 51(Suppl. 3):115-120.
38. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgansberger W., Di Marzo V., Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418(6897):530-534.
39. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutierrez S.O., van der Stelt M., Lopez-Rodriguez M.L., Casanova E., Schutz G., Zieglgansberger W., Di Marzo V., Behl C., Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302(5642):84-88.
40. McIntyre P., McLatchie L.M., Chambers A., Phillips E., Clarke M., Savidge J., Toms C., Peacock M., Shah K., Winter J., Weerasakera N., Webb M., Rang H.P., Bevan S., James I.F. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Br. J. Pharmacol. 2001, 132(5):1084-1094.
41. McIntyre D.C., Poulter M.O., Gilby K. Kindling: some old and some new. Epilepsy Res. 2002, 50(1-2):79-92.
42. Mezey E., Toth Z.E., Cortright D.N., Arzubi M.K., Krause J.E., Elde R., Guo A., Blumberg P.M., Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. U. S. A. 2000, 97(7):3655-3660.
43. Micale V., Di Marzo V., Sulcova A., Wotjak C.T., Drago F. Endocannabinoid system and mood disorders: priming a target for new therapies. Pharmacol. Ther. 2013, 138(1):18-37.
44. Monory K., Massa F., Egertova M., Eder M., Blaudzun H., Westenbroek R., Kelsch W., Jacob W., Marsch R., Ekker M., Long J., Rubenstein J.L., Goebbels S., Nave K.A., During M., Klugmann M., Wolfel B., Dodt H.U., Zieglgansberger W., Wotjak C.T., Mackie K., Elphick M.R., Marsicano G., Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 2006, 51(4):455-466.
45. Mori F., Ribolsi M., Kusayanagi H., Monteleone F., Mantovani V., Buttari F., Marasco E., Bernardi G., Maccarrone M., Centonze D. TRPV1 channels regulate cortical excitability in humans. J. Neurosci. 2012, 32(3):873-879.
46. Morimoto K., Fahnestock M., Racine R.J. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog. Neurobiol. 2004, 73(1):1-60.
47. Packard D.S., Menzies R.A., Skalko R.G. Incorporation of thymidine and its analogue, bromodeoxyuridine, into embryos and maternal tissues of the mouse. Differentiation 1973, 1(6):397-404.
48. Parent J.M., Janumpalli S., McNamara J.O., Lowenstein D.H. Increased dentate granule cell neurogenesis following amygdala kindling in the adult rat. Neurosci. Lett. 1998, 247(1):9-12.
49. Pekcec A., Muhlenhoff M., Gerardy-Schahn R., Potschka H. Impact of the PSA-NCAM system on pathophysiology in a chronic rodent model of temporal lobe epilepsy. Neurobiol. Dis. 2007, 27(1):54-66.
50. Pekcec A., Lupke M., Baumann R., Seifert H., Potschka H. Modulation of neurogenesis by targeted hippocampal irradiation fails to affect kindling progression. Hippocampus 2010, 21(8):866-876.
51. Peters J.H., McDougall S.J., Fawley J.A., Smith S.M., Andresen M.C. Primary afferent activation of thermosensitive TRPV1 triggers asynchronous glutamate release at central neurons. Neuron 2010, 65(5):657-669.
52. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4(11):873-884.
53. Pitkänen A., Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav. 2009, 14(1, Supplement 1):16-25.
54. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32(3):281-294.
55. Roberts J.C., Davis J.B., Benham C.D. [3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res. 2004, 995(2):176-183.
56. Ruehle S., Remmers F., Romo-Parra H., Massa F., Wickert M., Wörtge S., Häring M., Kaiser N., Marsicano G., Pape H.-C., Lutz B. Cannabinoid CB1 receptor in dorsal telencephalic glutamatergic neurons: distinctive sufficiency for hippocampus-dependent and amygdala-dependent synaptic and behavioral functions. J. Neurosci. 2013, 33(25):10264-10277.
57. Savidge J., Davis C., Shah K., Colley S., Phillips E., Ranasinghe S., Winter J., Kotsonis P., Rang H., McIntyre P. Cloning and functional characterization of the guinea pig vanilloid receptor 1. Neuropharmacology 2002, 43(3):450-456.
58. Shirazi M., Izadi M., Amin M., Rezvani M.E., Roohbakhsh A., Shamsizadeh A. Involvement of central TRPV1 receptors in pentylenetetrazole and amygdala-induced kindling in male rats. Neurol. Sci. 2014, 35(8):1235-1241.
59. Shoudai K., Peters J.H., McDougall S.J., Fawley J.A., Andresen M.C. Thermally active TRPV1 tonically drives central spontaneous glutamate release. J. Neurosci. 2010, 30(43):14470-14475.
60. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 2000, 129(2):227-230.
61. Sun F.J., Guo W., Zheng D.H., Zhang C.Q., Li S., Liu S.Y., Yin Q., Yang H., Shu H.F. Increased expression of TRPV1 in the cortex and hippocampus from patients with mesial temporal lobe epilepsy. J. Mol. Neurosci. 2013, 49(1):182-193.
62. Tellez-Zenteno J.F., Hernandez-Ronquillo L. A review of the epidemiology of temporal lobe epilepsy. Epilepsy Res. Treat. 2012, 2012:630853.
63. Toth A., Boczan J., Kedei N., Lizanecz E., Bagi Z., Papp Z., Edes I., Csiba L., Blumberg P.M. Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res. Mol. Brain Res. 2005, 135(1-2):162-168.
64. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1997, 83(2):393-411.
65. van Rijn C.M., Perescis M.F., Vinogradova L., van Luijtelaar G. Endocannabinoid system protects against cryptogenic seizures. Pharmacol. Rep. 2011, 63(1):165-168.
66. Varga A., Nemeth J., Szabo A., McDougall J.J., Zhang C., Elekes K., Pinter E., Szolcsanyi J., Helyes Z. Effects of the novel TRPV1 receptor antagonist SB366791 in vitro and in vivo in the rat. Neurosci. Lett. 2005, 385(2):137-142.
67. Volk H.A., Potschka H., Löscher W. Increased expression of the multidrug transporter P-glycoprotein in limbic brain regions after amygdala-kindled seizures in rats. Epilepsy Res. 2004, 58(1):67-79.
68. Wallace M.J., Blair R.E., Falenski K.W., Martin B.R., DeLorenzo R.J. The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. 2003, 307(1):129-137.
69. Wendt H., Soerensen J., Wotjak C.T., Potschka H. Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy in mice. Epilepsia 2011, 52(7):e62-e65.
70. Wyeth M.S., Zhang N., Mody I., Houser C.R. Selective reduction of cholecystokinin-positive basket cell innervation in a model of temporal lobe epilepsy. J. Neurosci. 2010, 30(26):8993-9006.